Teva Pharmaceutical Industries Limited Stock News

Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA, -0.11% gained 3% premarket on Wednesday after the company reported third-quarter sales that topped expectations and raised its

Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington's Disease, and said production in Israel was unaffected by the cou

Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday.

Two days ago, the Palestinian militant group Hamas launched a full-scale attack on Israel from the Gaza Strip. Since then, a full-scale conflict has escalated with many civilian casualties.

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday

Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI an

Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately b

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three pa

Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 8:40 AM ET Company Participants Richard Francis - Chief Executi

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global H

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivit

On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. Teva Pharmaceutical's revenue for the second quar

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.